188 related articles for article (PubMed ID: 17050578)
1. 3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children.
Cochereau I; Meddeb-Ouertani A; Khairallah M; Amraoui A; Zaghloul K; Pop M; Delval L; Pouliquen P; Tandon R; Garg P; Goldschmidt P; Bourcier T
Br J Ophthalmol; 2007 Apr; 91(4):465-9. PubMed ID: 17050578
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy assessment of azithromycin 1.5% eye drops versus tobramycin 0.3% on clinical signs of purulent bacterial conjunctivitis].
Robert PY; Bourcier T; Meddeb-Ouertani A; Khairallah M; Zaghloul K; Amraoui A; Bhagat Y; Pop M; Cochereau I
J Fr Ophtalmol; 2010 Apr; 33(4):241-8. PubMed ID: 20223555
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of azithromycin 1.5% eye drops in paediatric population with purulent bacterial conjunctivitis.
Bremond-Gignac D; Nezzar H; Bianchi PE; Messaoud R; Lazreg S; Voinea L; Speeg-Schatz C; Hartani D; Kaercher T; Kocyla-Karczmarewicz B; Murta J; Delval L; Renault D; Chiambaretta F;
Br J Ophthalmol; 2014 Jun; 98(6):739-45. PubMed ID: 24526744
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of azithromycin 1.5% eye drops for purulent bacterial conjunctivitis in pediatric patients.
Bremond-Gignac D; Mariani-Kurkdjian P; Beresniak A; El Fekih L; Bhagat Y; Pouliquen P; Delval L; Goldschmidt P; Bingen E; Cochereau I
Pediatr Infect Dis J; 2010 Mar; 29(3):222-6. PubMed ID: 19935122
[TBL] [Abstract][Full Text] [Related]
5. Microbiological efficacy of 3-day treatment with azithromycin 1.5% eye-drops for purulent bacterial conjunctivitis.
Denis F; Chaumeil C; Goldschmidt P; Delval L; Pouliquen P; Cochereau I; Chainier D; De Barbeyrac B
Eur J Ophthalmol; 2008; 18(6):858-68. PubMed ID: 18988154
[TBL] [Abstract][Full Text] [Related]
6. Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis.
Protzko E; Bowman L; Abelson M; Shapiro A;
Invest Ophthalmol Vis Sci; 2007 Aug; 48(8):3425-9. PubMed ID: 17652708
[TBL] [Abstract][Full Text] [Related]
7. Treatment of acute bacterial conjunctivitis: 1% fusidic acid viscous drops vs. 0.3% tobramycin drops.
Jackson WB; Low DE; Dattani D; Whitsitt PF; Leeder RG; MacDougall R
Can J Ophthalmol; 2002 Jun; 37(4):228-37; discussion 237. PubMed ID: 12095096
[TBL] [Abstract][Full Text] [Related]
8. Clinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double-masked clinical trial.
Abelson MB; Heller W; Shapiro AM; Si E; Hsu P; Bowman LM;
Am J Ophthalmol; 2008 Jun; 145(6):959-65. PubMed ID: 18374301
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis.
Torkildsen GL; Cockrum P; Meier E; Hammonds WM; Silverstein B; Silverstein S
Curr Med Res Opin; 2011 Jan; 27(1):171-8. PubMed ID: 21138337
[TBL] [Abstract][Full Text] [Related]
10. A clinical comparison of two formulations of tobramycin 0.3% eyedrops in the treatment of acute bacterial conjunctivitis.
Kernt K; Martinez MA; Bertin D; Stroman D; Cupp G; Martínez C; Tirado M; Guasch J;
Eur J Ophthalmol; 2005; 15(5):541-9. PubMed ID: 16167284
[TBL] [Abstract][Full Text] [Related]
11. A comparison of azithromycin and tobramycin eye drops on epithelial wound healing and tolerance after penetrating keratoplasty.
Blavin J; Sauer A; Saleh M; Gaucher D; Speeg-Schatz C; Bourcier T
J Ocul Pharmacol Ther; 2012 Aug; 28(4):428-32. PubMed ID: 22420841
[TBL] [Abstract][Full Text] [Related]
12. Topical lomefloxacin 0.3% twice daily versus tobramycin 0.3% in acute bacterial conjunctivitis: A multicenter double-blind phase III study.
Gallenga PE; Lobefalo L; Colangelo L; Della Loggia G; Orzalesi N; Velati P; Bujtar E; Ponte F; Damiani S; Bucci MG; Bonini S; Curatola MR; Palma LA; Bonomi L; Tomazzoli Gerosa L; Pagliarusco A; Milan E; Jauch A
Ophthalmologica; 1999; 213(4):250-7. PubMed ID: 10420109
[TBL] [Abstract][Full Text] [Related]
13. A 3-day regimen with azithromycin 1.5% eyedrops for the treatment of purulent bacterial conjunctivitis in children: efficacy on clinical signs and impact on the burden of illness.
Bremond-Gignac D; Messaoud R; Lazreg S; Speeg-Schatz C; Renault D; Chiambaretta F
Clin Ophthalmol; 2015; 9():725-32. PubMed ID: 25945033
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of effectiveness and tolerance of treatment with azithromycin 1.5% eye drops in bacterial conjunctivitis].
Ambroziak AM; Szaflik JP; Hapunik A
Klin Oczna; 2009; 111(1-3):46-9. PubMed ID: 19517846
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children.
Silverstein BE; Allaire C; Bateman KM; Gearinger LS; Morris TW; Comstock TL
Clin Ther; 2011 Jan; 33(1):13-26. PubMed ID: 21397770
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials.
Comstock TL; Paterno MR; Usner DW; Pichichero ME
Paediatr Drugs; 2010 Apr; 12(2):105-12. PubMed ID: 20218747
[TBL] [Abstract][Full Text] [Related]
17. Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and children.
DeLeon J; Silverstein BE; Allaire C; Gearinger LS; Bateman KM; Morris TW; Comstock TL
Clin Drug Investig; 2012 May; 32(5):303-17. PubMed ID: 22420526
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double-masked clinical trial.
Cochereau I; Goldschmidt P; Goepogui A; Afghani T; Delval L; Pouliquen P; Bourcier T; Robert PY
Br J Ophthalmol; 2007 May; 91(5):667-72. PubMed ID: 17005549
[TBL] [Abstract][Full Text] [Related]
19. Azithromycin 1.5% ophthalmic solution: in purulent bacterial or trachomatous conjunctivitis.
Garnock-Jones KP
Drugs; 2012 Feb; 72(3):361-73. PubMed ID: 22316352
[TBL] [Abstract][Full Text] [Related]
20. Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group.
Hyndiuk RA; Eiferman RA; Caldwell DR; Rosenwasser GO; Santos CI; Katz HR; Badrinath SS; Reddy MK; Adenis JP; Klauss V
Ophthalmology; 1996 Nov; 103(11):1854-62; discussion 1862-3. PubMed ID: 8942881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]